Drug Trial Radar · NCT03606408
Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699
Last checked: Nov 19, 2026Latest source record: Dec 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
127
Actual
Start
Oct 5, 2018
Primary completion
Nov 16, 2023
Study completion Nov 16, 2023
Sponsor
- Lead sponsor
- RECORDATI GROUPIndustry
- Sponsor type
- Industry
- First posted
- Jul 30, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is the evaluation of long-term safety of osilodrostat in patients who have already received osilodrostat treatment in a previous Global Novartis-sponsored trial and who, based on investigators' judgement, will continue benefiting with its administration.
Conditions
- Cushing's Syndrome
Interventions
osilodrostatDrug
osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse/Serious Adverse EventsTime frame: up to 5 years
Locations
56 sites in 21 countries. Site status is shown where the registry gives one.
University of Colorado
Aurora, Colorado
Emory University School of Medicine G2304 - C2301
Atlanta, Georgia
Northwestern University SC - LCI699C2301
Chicago, Illinois
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Columbia University Medical Center New York Presbyterian Neuroendocrine Unit
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Cleveland Clinic Foundation
Cleveland, Ohio
Oregon Health and Science University
Portland, Oregon
University of Pennsylvania Medical Center Univ Penn
Philadelphia, Pennsylvania
Medical College of Wisconsin MCW 2
Milwaukee, Wisconsin
Sanatorio Guemes
CABA, Buenos Aires, Argentina
Universitaetsklinik fuer Innere Medizin III
Vienna, Austria
Gasthuisberg University Hospital
Leuven, Belgium
Universidade Federal do Ceara
Fortaleza, Ceará, Brazil
Hospital Universitario Clementino Fraga Filho
Rio de Janeiro, Rio de Janeiro, Brazil
Hospital do Servidor Publico Estadual de Sao Paulo
São Paulo, São Paulo, Brazil
Hospital das Clinicas da Faculdade de Medicina da USP
São Paulo, São Paulo, Brazil
USHATE Akad Ivan Penchev
Sofia, Bulgaria
University of Alberta Hospital
Edmonton, Alberta, Canada
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada
Centre de recherche du CHUM CRCHUM
Montreal, Quebec, Canada
CHUS Hopital Fleurimont
Sherbrooke, Quebec, Canada
Peking University First Hospital
Beijing, China
Peking Union Medical College Hospital
Beijing, China
The First Affiliated Hopsital, Sun Yat-Sun University
Guangzhou, Guangdong, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Clinica Los Yoses
San Pedro, San Jose, Costa Rica, Costa Rica
Hopital Kremlin Bicetre
Le Kremlin-Bicêtre, France
CHRU de Lille
Lille, France
Hopital Cochin
Paris, France
CHU de Bordeaux
Pessac, Cedex, France
Universitaetsklinikum Erlangen Nuernberg
Erlangen, Germany
Universitaetsklinikum Muenchen LMU
München, Germany
All India Institute of Medical Sciences
New Delhi, India
A O Universitaria Policlinico Federico II Univ Studi Fed II
Naples, Italy
AOU Osp Riuniti Umberto I GM Lancisi G Salesi Univ Studi
Ancona, AN, Italy
Azienda Ospedaliera di Padova Università degli Studi
Padova, PD, Italy
Az Ospedaliero Universitaria Pisana Pres Osped di Cisanello
Pisa, PI, Italy
National Hospital Organization Nagoya Medical Center
Nagoya, Aichi-ken, Japan
Hyogo College of Medicine Hospital
Nishinomiya, Hyōgo, Japan
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.